Novel synthetic lethality drug target in urothelial bladder cancer based on MTAP genomic loss.

导出 LinkOut

翻译打印收藏纠错

作者： Michael F,Basin ^[1] ; Gennady,Bratslavsky ^[1] ; Nathan,Nahhas ^[1] ; Alina,Basnet ^[2] ; Hanan,Goldberg ^[1] ; Andrea,Necchi ^[3] ; Ethan S,Sokol ^[4] ; Shakti H,Ramkissoon ^[4] ; Richard S P,Huang ^[4] ; Jeffrey S,Ross ^[5] ; Joseph M,Jacob ^[6]

作者单位： Upstate Medical University Department of Urology, Syracuse, NY. ^[1] Upstate Medical University Department of Medicine, Syracuse, NY. ^[2] Vita-Salute San Raffaele University, Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy. ^[3] Foundation Medicine, Inc, Cambridge, MA. ^[4] Upstate Medical University Department of Urology, Syracuse, NY; Upstate Medical University Department of Medicine, Syracuse, NY; Vita-Salute San Raffaele University, Department of Medical Oncology, IRCCS Ospedale San Raffaele, Milan, Italy; Foundation Medicine, Inc, Cambridge, MA. ^[5] Upstate Medical University Department of Urology, Syracuse, NY. Electronic address: jacobj@upstate.edu. ^[6]

关键词 Bladder cancer Genomics MTAP

主题词人类(Humans);癌, 移行细胞(Carcinoma, Transitional Cell);膀胱肿瘤(Urinary Bladder Neoplasms);蛋白质精氨酸N-甲基转移酶(Protein-Arginine N-Methyltransferases);基因组学(Genomics)

DOI 10.1016/j.urolonc.2022.10.001

PMID 36443178

发布时间 2023-02-28

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交